Andrew M. Waters, PhD

Alharbi, Sara; Merkle, Svatava; Hammill, Adrienne M; Waters, Andrew M; Le Cras, Timothy D 2025. RAS Pathway Mutations and Therapeutics in Vascular Anomalies. Pediatric blood & cancer, 72 5, e31605

Alharbi, Sara; Merkle, Svatava; Hammill, Adrienne M; Waters, Andrew M; Le Cras, Timothy D 2025. RAS Pathway Mutations and Therapeutics in Vascular Anomalies. Pediatric blood & cancer, 72 5, e31605

Holderfield, Matthew; Lee, Bianca J; Jiang, Jingjing; Tomlinson, Aidan; Seamon, Kyle J; Mira, Alessia; Patrucco, Enrico; Goodhart, Grace; Dilly, Julien; Gindin, Yevgeniy; Dinglasan, Nuntana; Wang, Yingyun; Lai, Lick Pui; Cai, Shurui; Jiang, Lingyan; Nasholm, Nicole; Shifrin, Nataliya; Blaj, Cristina; Shah, Harshit; Evans, James W; Montazer, Nilufar; Lai, Oliver; Shi, Jade; Ahler, Ethan; Quintana, Elsa; Chang, Stephanie; Salvador, Anthony; Marquez, Abby; Cregg, Jim; Liu, Yang; Milin, Anthony; Chen, Anqi; Ziv, Tamar Bar; Parsons, Dylan; Knox, John E; Klomp, Jennifer E; Roth, Jennifer; Rees, Matthew; Ronan, Melissa; Cuevas-Navarro, Antonio; Hu, Feng; Lito, Piro; Santamaria, David; Aguirre, Andrew J; Waters, Andrew M; Der, Channing J; Ambrogio, Chiara; Wang, Zhengping; Gill, Adrian L; Koltun, Elena S; Smith, Jacqueline A M; Wildes, David; Singh, Mallika 2024. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature, ,

Long, Szu-Aun; Amparo, Amber M; Goodhart, Grace; Ahmad, Syed A; Waters, Andrew M 2024. Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment. Frontiers in oncology, 14 , 1402128

Loveless, Ian M; Kemp, Samantha B; Hartway, Kailee M; Mitchell, Jacob T; Wu, Yuesong; Zwernik, Samuel D; Salas-Escabillas, Daniel James; Brender, Sydney; George, Madison; Makinwa, Yetunde; Stockdale, Thais; Gartrelle, Kendyll; Reddy, Rohit G; Long, Daniel W; Wombwell, Allison; Clark, Julie M; Levin, Albert M; Kwon, David; Huang, Ling; Francescone, Ralph; Vendramini-Costa, Debora B; Stanger, Ben; Alessio, Adam; Waters, Andrew M; Cui, Yuehua; Fertig, Elana J; Kagohara, Luciane T; Theisen, Brian; Crawford, Howard C; Steele, Nina G 2024. Human pancreatic cancer single cell atlas reveals association of CXCL10+ fibroblasts and basal subtype tumor cells. Clinical cancer research : an official journal of the American Association for Cancer Research, ,

Nussbaum, Daniel P; Martz, Colin A; Waters, Andrew M; Barrera, Alejandro; Liu, Annie; Rutter, Justine C; Cerda-Smith, Christian G; Stewart, Amy E; Wu, Chao; Cakir, Merve; Levandowski, Cecilia B; Kantrowitz, David E; McCall, Shannon J; Pierobon, Mariaelena; Petricoin, Emanuel F; Joshua Smith, J; Reddy, Timothy E; Der, Channing J; Taatjes, Dylan J; Wood, Kris C 2024. Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancers. NPJ precision oncology, 8 1, 124

Edwards, A Cole; Stalnecker, Clint A; Jean Morales, Alexis; Taylor, Khalilah E; Klomp, Jennifer E; Klomp, Jeffrey A; Waters, Andrew M; Sudhakar, Niranjan; Hallin, Jill; Tang, Tracy T; Olson, Peter; Post, Leonard; Christensen, James G; Cox, Adrienne D; Der, Channing J 2023. TEAD Inhibition Overcomes YAP1/TAZ-driven Primary and Acquired Resistance to KRASG12C Inhibitors. Cancer research, ,

Goodwin, Craig M; Waters, Andrew M; Klomp, Jennifer E; Javaid, Sehrish; Bryant, Kirsten L; Stalnecker, Clint A; Drizyte-Miller, Kristina; Papke, Bjoern; Yang, Runying; Amparo, Amber M; Ozkan-Dagliyan, Irem; Baldelli, Elisa; Calvert, Valerie; Pierobon, Mariaelena; Sorrentino, Jessica A; Beelen, Andrew P; Bublitz, Natalie; Lüthen, Mareen; Wood, Kris C; Petricoin, Emanuel F; Sers, Christine; McRee, Autumn J; Cox, Adrienne D; Der, Channing J 2023. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. Cancer research, 83 1, 141-157

Cook, Danielle R; Kang, Melissa; Martin, Timothy D; Galanko, Joseph A; Loeza, Gabriela H; Trembath, Dimitri G; Justilien, Verline; Pickering, Karen A; Vincent, David F; Jarosch, Armin; Jurmeister, Philipp; Waters, Andrew M; Hibshman, Priya S; Campbell, Andrew D; Ford, Catriona A; Keku, Temitope O; Yeh, Jen Jen; Lee, Michael S; Cox, Adrienne D; Fields, Alan P; Sandler, Robert S; Sansom, Owen J; Sers, Christine; Schaefer, Antje; Der, Channing J 2022. Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth. Cancer research, 82 1, 90-104

Huynh, Minh V; Hobbs, G Aaron; Schaefer, Antje; Pierobon, Mariaelena; Carey, Leiah M; Diehl, J Nathaniel; DeLiberty, Jonathan M; Thurman, Ryan D; Cooke, Adelaide R; Goodwin, Craig M; Cook, Joshua H; Lin, Lin; Waters, Andrew M; Rashid, Naim U; Petricoin, Emanuel F; Campbell, Sharon L; Haigis, Kevin M; Simeone, Diane M; Lyssiotis, Costas A; Cox, Adrienne D; Der, Channing J 2022. Functional and biological heterogeneity of KRASQ61 mutations. Science signaling, 15 746, eabn2694

Javaid, Sehrish; Schaefer, Antje; Goodwin, Craig M; Nguyen, Victoria V; Massey, Frances L; Pierobon, Mariaelena; Gambrell-Sanders, Da'Jhnae; Waters, Andrew M; Lambert, Kathryn N; Diehl, J Nathaniel; Hobbs, G Aaron; Wood, Kris C; Petricoin, Emanuel F; Der, Channing J; Cox, Adrienne D 2022. Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma. Molecular cancer therapeutics, 21 5, 762-774

Klomp, Jennifer E; Lee, Ye S; Goodwin, Craig M; Papke, Björn; Klomp, Jeff A; Waters, Andrew M; Stalnecker, Clint A; DeLiberty, Jonathan M; Drizyte-Miller, Kristina; Yang, Runying; Diehl, J Nathaniel; Yin, Hongwei H; Pierobon, Mariaelena; Baldelli, Elisa; Ryan, Meagan B; Li, Siqi; Peterson, Jackson; Smith, Amber R; Neal, James T; McCormick, Aaron K; Kuo, Calvin J; Counter, Christopher M; Petricoin, Emanuel F; Cox, Adrienne D; Bryant, Kirsten L; Der, Channing J 2021. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Cell reports, 37 9, 110060

Waters, Andrew M; Der, Channing J 2021. Validation of Isoform- and Mutation-Specific RAS Antibodies. Methods in molecular biology (Clifton, N.J.), 2262 , 91-103

Waters, Andrew M; Khatib, Tala O; Papke, Bjoern; Goodwin, Craig M; Hobbs, G Aaron; Diehl, J Nathaniel; Yang, Runying; Edwards, A Cole; Walsh, Katherine H; Sulahian, Rita; McFarland, James M; Kapner, Kevin S; Gilbert, Thomas S K; Stalnecker, Clint A; Javaid, Sehrish; Barkovskaya, Anna; Grover, Kajal R; Hibshman, Priya S; Blake, Devon R; Schaefer, Antje; Nowak, Katherine M; Klomp, Jennifer E; Hayes, Tikvah K; Kassner, Michelle; Tang, Nanyun; Tanaseichuk, Olga; Chen, Kaisheng; Zhou, Yingyao; Kalkat, Manpreet; Herring, Laura E; Graves, Lee M; Penn, Linda Z; Yin, Hongwei H; Aguirre, Andrew J; Hahn, William C; Cox, Adrienne D; Der, Channing J 2021. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Cell reports, 35 13, 109291

Bryant, Kirsten L; Stalnecker, Clint A; Zeitouni, Daniel; Klomp, Jennifer E; Peng, Sen; Tikunov, Andrey P; Gunda, Venugopal; Pierobon, Mariaelena; Waters, Andrew M; George, Samuel D; Tomar, Garima; Papke, Björn; Hobbs, G Aaron; Yan, Liang; Hayes, Tikvah K; Diehl, J Nathaniel; Goode, Gennifer D; Chaika, Nina V; Wang, Yingxue; Zhang, Guo-Fang; Witkiewicz, Agnieszka K; Knudsen, Erik S; Petricoin, Emanuel F; Singh, Pankaj K; Macdonald, Jeffrey M; Tran, Nhan L; Lyssiotis, Costas A; Ying, Haoqiang; Kimmelman, Alec C; Cox, Adrienne D; Der, Channing J 2020. Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nature medicine, 26 6, 982

Hobbs, G Aaron; Baker, Nicole M; Miermont, Anne M; Thurman, Ryan D; Pierobon, Mariaelena; Tran, Timothy H; Anderson, Andrew O; Waters, Andrew M; Diehl, J Nathaniel; Papke, Bjoern; Hodge, Richard G; Klomp, Jennifer E; Goodwin, Craig M; DeLiberty, Jonathan M; Wang, Junning; Ng, Raymond W S; Gautam, Prson; Bryant, Kirsten L; Esposito, Dominic; Campbell, Sharon L; Petricoin, Emanuel F; Simanshu, Dhirendra K; Aguirre, Andrew J; Wolpin, Brian M; Wennerberg, Krister; Rudloff, Udo; Cox, Adrienne D; Der, Channing J 2020. Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Cancer discovery, 10 1, 104-123

Ozkan-Dagliyan, Irem; Diehl, J Nathaniel; George, Samuel D; Schaefer, Antje; Papke, Bjoern; Klotz-Noack, Kathleen; Waters, Andrew M; Goodwin, Craig M; Gautam, Prson; Pierobon, Mariaelena; Peng, Sen; Gilbert, Thomas S K; Lin, Kevin H; Dagliyan, Onur; Wennerberg, Krister; Petricoin, Emanuel F; Tran, Nhan L; Bhagwat, Shripad V; Tiu, Ramon V; Peng, Sheng-Bin; Herring, Laura E; Graves, Lee M; Sers, Christine; Wood, Kris C; Cox, Adrienne D; Der, Channing J 2020. Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. Cell reports, 31 11, 107764

Bryant, Kirsten L; Stalnecker, Clint A; Zeitouni, Daniel; Klomp, Jennifer E; Peng, Sen; Tikunov, Andrey P; Gunda, Venugopal; Pierobon, Mariaelena; Waters, Andrew M; George, Samuel D; Tomar, Garima; Papke, Björn; Hobbs, G Aaron; Yan, Liang; Hayes, Tikvah K; Diehl, J Nathaniel; Goode, Gennifer D; Chaika, Nina V; Wang, Yingxue; Zhang, Guo-Fang; Witkiewicz, Agnieszka K; Knudsen, Erik S; Petricoin, Emanuel F; Singh, Pankaj K; Macdonald, Jeffrey M; Tran, Nhan L; Lyssiotis, Costas A; Ying, Haoqiang; Kimmelman, Alec C; Cox, Adrienne D; Der, Channing J 2019. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nature medicine, 25 4, 628-640

Waters, Andrew M; Der, Channing J 2018. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harbor perspectives in medicine, 8 9,

Yuan, Tina L; Amzallag, Arnaud; Bagni, Rachel; Yi, Ming; Afghani, Shervin; Burgan, William; Fer, Nicole; Strathern, Leslie A; Powell, Katie; Smith, Brian; Waters, Andrew M; Drubin, David; Thomson, Ty; Liao, Rosy; Greninger, Patricia; Stein, Giovanna T; Murchie, Ellen; Cortez, Eliane; Egan, Regina K; Procter, Lauren; Bess, Matthew; Cheng, Kwong Tai; Lee, Chih-Shia; Lee, Liam Changwoo; Fellmann, Christof; Stephens, Robert; Luo, Ji; Lowe, Scott W; Benes, Cyril H; McCormick, Frank 2018. Differential Effector Engagement by Oncogenic KRAS. Cell reports, 22 7, 1889-1902

Waters, Andrew M; Ozkan-Dagliyan, Irem; Vaseva, Angelina V; Fer, Nicole; Strathern, Leslie A; Hobbs, G Aaron; Tessier-Cloutier, Basile; Gillette, William K; Bagni, Rachel; Whiteley, Gordon R; Hartley, James L; McCormick, Frank; Cox, Adrienne D; Houghton, Peter J; Huntsman, David G; Philips, Mark R; Der, Channing J 2017. Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. Science signaling, 10 498,

Ye, Xiaoying; Chan, King C; Waters, Andrew M; Bess, Matthew; Harned, Adam; Wei, Bih-Rong; Loncarek, Jadranka; Luke, Brian T; Orsburn, Benjamin C; Hollinger, Bradley D; Stephens, Robert M; Bagni, Rachel; Martinko, Alex; Wells, James A; Nissley, Dwight V; McCormick, Frank; Whiteley, Gordon; Blonder, Josip 2016. Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface. Oncotarget, 7 52, 86948-86971

Waters, Andrew M; Bagni, Rachel; Portugal, Franklin; Hartley, James L . Single Synonymous Mutations in KRAS Cause Transformed Phenotypes in NIH3T3 Cells. PloS one, 11 9, e0163272